|10.01||-0.0200||-0.20%||Vol 602||1Y Perf 0.30%|
|May 18th, 2022 15:59 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||69.09||Earnings Rating||—|
|Market Cap||230.23M||Earnings Date||-|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||860|
|Avg. Monthly Volume||39.62K|
|Avg. Quarterly Volume||15.26K|
Biotech Acquisition Company Unit (NASDAQ: BIOTU) stock closed at 10.03 per share at the end of the most recent trading day (a -0.1% change compared to the prior day closing price) with a volume of 300.0000 shares and market capitalization of 230.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the industry, sector and employs 0 people. Biotech Acquisition Company Unit CEO is .
The one-year performance of Biotech Acquisition Company Unit stock is 0.3%, while year-to-date (YTD) performance is -1.09%. BIOTU stock has a five-year performance of %. Its 52-week range is between 9.295 and 10.3299, which gives BIOTU stock a 52-week price range ratio of 69.09%
Biotech Acquisition Company Unit currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -5.96%, a ROC of -6.79% and a ROE of -6.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Biotech Acquisition Company Unit, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biotech Acquisition Company Unit’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biotech Acquisition Company Unit is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Biotech Acquisition Company Unit stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biotech Acquisition Company Unit has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biotech Acquisition Company Unit has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.98, ATR14 : 0.05, CCI20 : 60.23, Chaikin Money Flow : 0.22, MACD : 0.03, Money Flow Index : 6.78, ROC : 0.91, RSI : 55.92, STOCH (14,3) : 91.49, STOCH RSI : 0.26, UO : 68.64, Williams %R : -8.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biotech Acquisition Company Unit in the last 12-months were:
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.